Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831
AUTOR(ES)
Halyard, Michele Y.
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2690390Documentos Relacionados
- 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
- Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
- Clinical outcome data for symptomatic breast cancer: the breast cancer clinical outcome measures (BCCOM) project
- Clinical outcome data for symptomatic breast cancer: the Breast Cancer Clinical Outcome Measures (BCCOM) project